Biologic or targeted synthetic DMARD

PreclinicalSmall molecule

Biologic or targeted synthetic DMARD is one of 52 small molecule programs targeting Psoriatic Arthritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Psoriatic ArthritisActive, not recruiting

Psoriatic ArthritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Psoriatic Arthritis

#DrugCompanyPhaseTrials

Bimzelx

UCB

Phase 3

9 2

Skyrizi

AbbVie

Phase 3

8 3

Jyseleca

Gilead

Phase 3

4 4

Taxol

Teva

Phase 3

1 5

Keytruda

Merck & Co.

Phase 3

1 6

Icotyde

Johnson & Johnson

Phase 3

1 7

Xeljanz

PPrism Pharmaceuticals

Phase 3

8 8

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Recruiting

Targeted Therapy

NCT01965132

Clinical

Trials by Indication[1]

Targeted Therapy1 trial

Korean College of Rheumatology Biologics and Targeted Therapy Registry

Recruiting·SSeoul National University Hospital··NCT01965132·10,000 enrolled

Psoriatic Arthritis1 trial

A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis

Not yet recruiting·RRoyal United Hospitals Bath NHS Foundation Trust··NCT07417995·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Biologic or targeted synthetic DMARD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biologic or targeted synthetic DMARD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biologic or targeted synthetic DMARD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeoul National University Hospital

Biologic or targeted synthetic DMARD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Targeted Therapy1 trial

Psoriatic Arthritis1 trial

References

Drug Info

Quick Facts

Related News